Literature DB >> 9038732

p53 expression in carcinoma of the cervix.

C R Hunt1, R J Hale, C H Buckley, J Hunt.   

Abstract

AIM: To assess overexpression of the proposed tumour suppressor gene product p53 using the mouse monoclonal antibody DO-7 in the three main subtypes of carcinoma of the uterine cervix and to evaluate its value as a prognostic indicator.
METHODS: Eighty two cases of FIGO Stage IB/IIA uterine cervical carcinoma were studied retrospectively. The tumours had been previously typed into adenocarcinomas, squamous carcinomas and adenosquamous carcinomas after the tissue had been fixed in formalin and embedded in paraffin wax. p53 protein expression was assessed using a standard immunohistochemical technique and the findings were correlated with tumour type, lymph node status and clinical outcome.
RESULTS: In total, the p53 gene product was overexpressed in 17.1% (14/82) of all carcinomas and also in areas of cervical intraepithelial neoplasia grade III adjacent to invasive squamous carcinoma. Where present, the normal epithelium was uniformly negative. No association was found between p53 overexpression and tumour subtype, lymph node status or clinical outcome.
CONCLUSIONS: It seems unlikely that p53 analysis will be of value in determining prognosis in carcinoma of the uterine cervix.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9038732      PMCID: PMC499643          DOI: 10.1136/jcp.49.12.971

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  30 in total

1.  Mutant p53 product in patients with stage III cervical cancer.

Authors:  G Gitsch; C Kainz; E Joura; G Breitenecker
Journal:  Anticancer Res       Date:  1992 Nov-Dec       Impact factor: 2.480

2.  p53 mutations in HPV-negative cervical carcinoma.

Authors:  D J Park; S P Wilczynski; R L Paquette; C W Miller; H P Koeffler
Journal:  Oncogene       Date:  1994-01       Impact factor: 9.867

3.  Mutations of p53 and human papillomavirus infection in cervical carcinoma.

Authors:  R L Paquette; Y Y Lee; S P Wilczynski; A Karmakar; M Kizaki; C W Miller; H P Koeffler
Journal:  Cancer       Date:  1993-08-15       Impact factor: 6.860

4.  Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri.

Authors:  R Holm; H Skomedal; A Helland; G Kristensen; A L Børresen; J M Nesland
Journal:  J Pathol       Date:  1993-01       Impact factor: 7.996

5.  An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms.

Authors:  I O Baas; J W Mulder; G J Offerhaus; B Vogelstein; S R Hamilton
Journal:  J Pathol       Date:  1994-01       Impact factor: 7.996

6.  Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas.

Authors:  A Helland; R Holm; G Kristensen; J Kaern; F Karlsen; C Trope; J M Nesland; A L Børresen
Journal:  J Pathol       Date:  1993-10       Impact factor: 7.996

7.  p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix.

Authors:  S Bosari; M Roncalli; G Viale; P Bossi; G Coggi
Journal:  J Pathol       Date:  1993-04       Impact factor: 7.996

8.  p53CM1 expression is not associated with prognosis in uterine cervical carcinoma.

Authors:  K Oka; T Nakano; T Arai
Journal:  Cancer       Date:  1993-07-01       Impact factor: 6.860

Review 9.  The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis.

Authors:  A J Levine; M E Perry; A Chang; A Silver; D Dittmer; M Wu; D Welsh
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

10.  p53 mutations in cervical carcinogenesis--low frequency and lack of correlation with human papillomavirus status.

Authors:  R M Busby-Earle; C M Steel; A R Williams; B Cohen; C C Bird
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

View more
  6 in total

1.  Expression of E6, p53 and p21 proteins and physical state of HPV16 in cervical cytologies with and without low grade lesions.

Authors:  Diana K Jiménez Tagle; Daniel Hernández Sotelo; Berenice Illades-Aguiar; Marco A Leyva-Vazquez; Eugenia Flores Alfaro; Yaneth Castro Coronel; Oscar Del Moral Hernández; Luz Del Carmen Alarcón Romero
Journal:  Int J Clin Exp Med       Date:  2014-01-15

2.  Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.

Authors:  Shinichi Togami; Yuko Sasajima; Takahiro Kasamatsu; Rie Oda-Otomo; Satoshi Okada; Mitsuya Ishikawa; Shun-ichi Ikeda; Tomoyasu Kato; Hitoshi Tsuda
Journal:  Pathol Oncol Res       Date:  2014-11-05       Impact factor: 3.201

3.  Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease.

Authors:  Shigeki Shiohara; Tanri Shiozawa; Tsutomu Miyamoto; Yu-Zhen Feng; Hiroyasu Kashima; Miyuki Kurai; Akihisa Suzuki; Ikuo Konishi
Journal:  Virchows Arch       Date:  2005-05-13       Impact factor: 4.064

4.  p53 immunohistochemical expression of Egyptian cervical carcinoma.

Authors:  H Abd El All; A Rye; P Duvillard
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

5.  The Role of p53 Gene in Cervical Carcinogenesis.

Authors:  Sulekha Pandey; L K Pandey; A K Saxena; Nidhi Patel
Journal:  J Obstet Gynaecol India       Date:  2015-09-04

6.  Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer.

Authors:  R A Crawford; C Caldwell; R K Iles; D Lowe; J H Shepherd; T Chard
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.